Cisapride is known to accelerate gastrointestinal motility in various diseases with gastrointestinal motor abnormalities, and in normal subjects. In this study, we developed a new method to evaluate intestinal transit by radio-opaque markers, and evaluated the effect of oral doses of cisapride on intestinal transit in 6 normal subjects. Twenty markers were ingested with breakfast, and abdominal...

In the present study the electrophysiological characteristics and the proarrhythmic potential of cisapride and a structurally related drug, mosapride, were compared. In the anesthetized guinea pig, cisapride and d-sotalol (0.01-10 micromol/kg i.v., n = 6) dose-dependently prolonged the duration of the monophasic action potential recorded from the left ventricle. The maximal lengthening was 18 +...

The Medicines Control Agency and the Committee on Safety of Medicines (CSM) recently stated that cisapride is contraindicated in infants born before 36 weeks’ gestation for three months after birth, and that there is insuYcient data to support the use of cisapride in children up to 12 years of age. These statements need qualification. Many believe cisapride to be a safe and useful agent in a va...

The Medicines Control Agency and the Committee on Safety of Medicines (CSM) recently stated that cisapride is contraindicated in infants born before 36 weeks’ gestation for three months after birth, and that there is insuYcient data to support the use of cisapride in children up to 12 years of age. These statements need qualification. Many believe cisapride to be a safe and useful agent in a va...

OBJECTIVE: To evaluate the effect of cisapride and chest physical therapy on the gastroesophageal reflux of wheezing babies. METHODS: We prospectively assessed the presence of technetium ((99)Tc) in the upper, middle, and lower esophagus of 25 wheezing babies (13 with GERD and 12 without GERD) using scintigraphy. Both groups underwent clinical investigation, including laboratory, X-ray and scin...

OBJECTIVE To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients. DESIGN Randomised, double blind, placebo controlled study. SETTING 65 primary care practices in Norway. PARTICIPANTS 483 untreated patients with complaints of heartburn >/=3 days a week, with at most grade 1 reflux oesophagitis. INTERVENTI...

OBJECTIVES Life-threatening arrhythmias and prolonged QT interval have been reported in adults and children using cisapride, a medication structurally similar to procainamide. Premature infants have reduced activity of cytochrome p-450, the system responsible for metabolism of cisapride, which could lead to QT prolongation. Therefore, we prospectively studied premature infants and children rece...

BACKGROUND & OBJECTIVES Cisapride is a prokinetic agent with cholinomimetic and 5-HT4 receptor agonistic properties. It has been proposed that cisapride-induced hypotension is partly mediated by cholinergic system. The aim of this study was to investigate the mechanism of cisapride-induced dilatation in the rat isolated perfused kidney. METHODS Left kidneys of Wistar rats were isolated and pe...

The effects of cisapride (10 mg three times daily) on the stool evacuation characteristics, laxative consumption (symptom diary) and motility pattern (rectoanal manometry) were assessed in patients with chronic idiopathic constipation who fulfilled Rome II criteria. After a 14-day basal period on a diet rich in fiber (phase I), patients were treated with placebo (n = 20) or cisapride (n = 19) (...

AIM Prospective survey of the effects of cisapride on QTc interval in neonates given cisapride. METHODS QTc interval was determined just before and 2.9 (0.9) days after outset of the treatment in 49 neonates treated with cisapride between 1 August 1995 and 29 February 1996. RESULTS Cisapride significantly increased QTc interval (p = 0.0001), and this was higher when birthweight or gestation...